Codex_V5

Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy.

Pubmed_id: 21295516
Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
Genbank_id: No known Genbank_id
Date: Apr 2011
Volume: 50
Issue: 4
Pages: 287-91
Author(s): Chou S,

Abstract: Results add to known exonuclease domain mutations that confer ganciclovir-cidofovir cross-resistance, polymerase domain mutations that confer foscarnet resistance with variably decreased ganciclovir/cidofovir susceptibility, and increase the list of sequence variants with no measurable impact on drug susceptibility. The phenotypic diversity of similar UL54 genotypic variants complicates the interpretation of genotypic resistance testing. Technical improvements are facilitating the phenotyping of remaining unknown sequence variants.

Mutant	Gene	Virus	Antiviral	EC50 ratio	Phenotype
F412L	UL54	Human betaherpesvirus 5	Ganciclovir	4.60	Intermediate level resistance
F412L	UL54	Human betaherpesvirus 5	Cidofovir	9.40	High level resistance
F412L	UL54	Human betaherpesvirus 5	Foscarnet	1.10	No resistance
F412S	UL54	Human betaherpesvirus 5	Ganciclovir	5.30	High level resistance
F412S	UL54	Human betaherpesvirus 5	Cidofovir	13.00	High level resistance
F412S	UL54	Human betaherpesvirus 5	Foscarnet	0.80	No resistance
L545W	UL54	Human betaherpesvirus 5	Ganciclovir	4.90	Intermediate level resistance
L545W	UL54	Human betaherpesvirus 5	Cidofovir	6.30	High level resistance
L545W	UL54	Human betaherpesvirus 5	Foscarnet	1.30	No resistance
Q578H	UL54	Human betaherpesvirus 5	Ganciclovir	3.30	Intermediate level resistance
Q578H	UL54	Human betaherpesvirus 5	Cidofovir	2.30	Low level resistance
Q578H	UL54	Human betaherpesvirus 5	Foscarnet	4.50	Intermediate level resistance